Bisubstrate enzymes, such as 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), exist in solution as an ensemble of conformations. 17β-HSD1 catalyzes the last step of the biosynthesis of estradiol and, thus, it is a potentially attractive target for breast cancer treatment.
To elucidate the conformational transitions of its catalytic cycle, a structural analysis of all available crystal structures was performed and representative conformations were assigned to each step of the putative kinetic mechanism. To cover most of the conformational space, all-atom molecular dynamic simulations were performed using the four crystallographic structures best describing apoform, opened, occluded and closed state of 17β-HSD1 as starting structures. With three of them, binary and ternary complexes were built with NADPH and NADPH-estrone, respectively, while two were investigated as apoform. Free energy calculations were performed in order to judge more accurately which of the MD complexes describes a specific kinetic step.
Remarkably, the analysis of the eight long range trajectories resulting from this multi-trajectory/-complex approach revealed an essential role played by the backbone and side chain motions, especially of the βFαG′-loop, in cofactor and substrate binding. Thus, a selected-fit mechanism is suggested for 17β-HSD1, where ligand-binding induced concerted motions of the FG-segment and the C-terminal part guide the enzyme along its preferred catalytic pathway. Overall, we could assign different enzyme conformations to the five steps of the random bi-bi kinetic cycle of 17β-HSD1 and we could postulate a preferred pathway for it. This study lays the basis for more-targeted biochemical studies on 17β-HSD1, as well as for the design of specific inhibitors of this enzyme. Moreover, it provides a useful guideline for other enzymes, also characterized by a rigid core and a flexible region directing their catalysis.
Citation: Negri M, Recanatini M, Hartmann RW (2010) Insights in 17β-HSD1 Enzyme Kinetics and Ligand Binding by Dynamic Motion Investigation. PLoS ONE 5(8): e12026. https://doi.org/10.1371/journal.pone.0012026
Editor: Floyd Romesberg, The Scripps Research Institute, United States of America
Received: March 29, 2010; Accepted: July 6, 2010; Published: August 10, 2010
Copyright: © 2010 Negri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing interests: The authors have declared that no competing interests exist.
Cytoplasmic proteins are present in solution as an ensemble of conformations, which are in a dynamic equilibrium, strongly influenced by the presence of ligands (in case of enzymes: cofactors, substrates, inhibitors, or other proteins). This is especially true for enzymes following a bisubstrate kinetic, like Escherichia coli dihydrofolate reductase (DHFR)  and human 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1 or SDR28C1, according to the new nomenclature ; E.C. 188.8.131.52), where concerted dynamic motions are necessary between the enzyme conformations responsible for specific kinetic steps. An in-depth knowledge of both protein dynamic and its influence on ligand binding could effectively speed up rational drug design . These new drugs might act not only by competing with the substrate for its binding site, but also by inducing a dynamic dysfunction of the enzyme by hindering the switch between its conformations .
In estrogen target cells 17β-HSD1 catalyzes the NADPH-dependent reduction of estrone (E1) to the biologically highly potent 17β-estradiol (E2) – (Figure 1). It has been shown that in post-menopausal women with hormone-dependent breast cancer tumor proliferation is driven by increased levels of E2 –. As 17β-HSD1 is often overexpressed in breast tumor cells, it is considered as a novel therapeutic target –.
The substrate E1 is colored in blue, the cofactor NADPH in red. Amino acids, which are either involved in the catalysis or are responsible for ligand/cofactor stabilization, are colored in black and residue labelled. The hydrogen bonds are in dashed lines while the proton transfers are highlighted with arrows.
Recently, Cooper et al. elucidated the complete kinetic mechanism for the rat liver 3α-HSD and could assign different enzyme forms to the specific reaction coordinates . 3α-HSD and nearly all other HSD enzymes are described to follow a sequential ordered bi-bi kinetic mechanism, where the cofactor enters first and exits last. The kinetic mechanism of 17β-HSD1 is still not fully clarified, although it has been reported to follow a rapid equilibrium random bi-bi mechanism (Figure S1), a peculiarity compared to other HSDs –. The high NADPH/NADP+ gradient (>500∶1) and the excess of NADPH with respect to E1 in vivo, as well as the thermodynamically favoured NADPH oxidation –, suggest the presence of NADPH in the enzyme prior to steroid binding. Asn114, Ser142, Tyr155 and Lys159 form the catalytic tetrad of 17β-HSD1 , conserved in many HSD enzymes, and are involved in the pro-S hydride transfer from NADPH to the α-face of the C17 carbon as well as in the proton transfer between the OH group of Tyr155 and the C17 oxygen of E1  (Figure 2).
The substrate E1 is represented in blue, the cofactor NADPH in red. The amino acids, which are either involved in the catalysis or are responsible for ligand/cofactor stabilization, are colored in black and residue labelled. The hydrogen bonds are in dashed lines while the proton transfers are highlighted with arrows.
Remarkably, the catalytic reaction of 17β-HSD1 is reversible in vitro; but it is unidirectional in vivo, because of the abundance of NADPH. No crystal structure of the ternary complex enzyme (E)-NADPH-E1 exists. We think that possible reasons for that might be problems in the crystallization process, i.e. low electron density for E1, but also the very fast transfer rate observed for the reduction of E1 (kcat 1.5 s−1 for dimer ; 2.9 s−1 ). E2 has a two order of magnitude reduced binding affinity to 17β-HSD1 (KM 4.6 µM) compared to that of E1 (KM 0.03 µM), but a similar (less reduced) kcat of 2.0 s−1 . However, discordant kcat and KM values are reported in literature for both E1 and E2, in part depending on the cofactor used for the experiment (NADPH or NADH), its concentration (20 or 50 µM), etc. –, , – The kcat and KM values reported here were obtained using NADP(H). Due to the excess of NADPH over NADP+ and due to the marked specificity of 17β-HSD1 for the E1 reduction using NADPH instead of NADP+ as cofactor (about 240-fold higher than for E2 oxidation) , we prospect that in vivo the backward reaction E2 to E1 does not take place. Moreover, the KM of E1 is 12-fold lower when using NADPH (0.03 µM) than when using NADH (0.36 µM), hence underlining the crucial role played by the third phosphate group of the cofactor in the E1 reduction .
Steroidal and non-steroidal inhibitors of 17β-HSD1 have been reported (Figure 1) –, –. The former mimic the substrate and are supposed to bind in the substrate binding site (SUB), a narrow hydrophobic tunnel . They are stabilized by hydrogen bonds with Tyr155/Ser142 and His221/Glu282, located on both ends of the pocket, and, further, by hydrophobic contacts  Recently, Poirier et al. published a series of hybrid inhibitors, based on a E1/E2 core with substituents of various lengths in C16 position . These inhibitors occupy both the SUB and the COF (cofactor binding site), competing with E1 and NADPH, as demonstrated by the binary complex E-HYC (PDB entry 1i5r). Up to now no crystallographic data exists describing the binding mode of non-steroidal inhibitors, although computational studies performed by various groups suggested some classes of non-steroidals to bind like their steroidal analogues in the SUB –, – and others to occupy only partially the SUB protruding into the COF, like compound 1 .
Herein, we present the first, to our knowledge, computational investigation of the kinetic mechanism of 17β-HSD1, one of the thirteen 17β-HSDs belonging to the short-chain dehydrogenases/reductases (SDR), a large superfamily of NAD(P)H-dependent enzymes. Furthermore, the linkage between representative enzyme conformations and the five steps described for the random bi-bi mechanism, an in-depth computational analysis of the flexible βFαG′-loop, and its role in enzyme catalysis and in ligand binding were elucidated. Thus, a multi-trajectory/-complex molecular dynamic (MD) strategy was followed, based on four different enzyme conformations. Molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) methods , in combination with normal-mode analysis (NMODE) , were exploited to calculate the free energies of the complexes with the aim to substantiate our kinetic hypothesis and to determine the best enzyme conformation for binding of E1 and NADPH, respectively.
Moreover, we analyzed the kinetic mechanism of 17β-HSD1 by means of MD simulations in order to enlarge the conformational sampling of the enzyme structures. This ensemble of conformers should be used to improve drug-design through the identification of new inhibitor binding modes. In particular, making a parallel to E. coli DHFR which also has a bi-bi kinetics, our long range goal is to design 17β-HSD1 inhibitors able to “freeze” the enzyme in one of its kinetic substates, hindering the evolution of the kinetic cycle, in a similar way as methotrexate (MTX) does in DHFR .
Results and Discussion
1. Structural analysis of human 17β-HSD1 crystal structures
17β-HSD1 is a homodimeric protein and shows the typical rigid β-α-β fold of the SDR-family with a core of parallel β-strands fanning across the center and α-helices draped on the outside (Figure S2) , resulting in a rigid COF at the N-terminus and a structurally variable C-terminus, hosting the SUB . The structurally conserved region comprises Rossman fold and GxxxGxG motif (G is glycine and x any other residue), characteristic of oxidation/reduction enzymes that bind nicotinamide cofactors, plus the YxxxK sequence (Y is Tyr155 and K Lys159) that participates in catalysis . In sharp contrast to other 17β-HSDs, type 1 is characterized by a long, flexible βFαG′-loop and a C-terminal helix, both delimiting the SUB and probably involved in enzymatic catalysis and in entrance and exit mechanisms of small molecules.
Until May 2010 twenty crystal structures of 17β-HSD1 were available in the Protein Data Bank (PDB) as apoform, binary or ternary complex (Table 1). The loop residues Thr190-Gly198 of the PBD entry 1fdt  were modelled in two different conformations and had been considered as two different conformers, denoted hereafter as 1fdtA and 1fdtB. Superimposition of all crystals gave a mean backbone RMSD (root mean-square distance) of ca. 0.5 Å (all-atom RMSD ca. 1.5 Å). The only flexible part was identified in the above mentioned βFαG′-loop, which could adopt different conformations, strongly modulating shape and volume of the active site (including both COF and SUB). Eight of these crystal structures were incomplete, missing mainly the loop residues Phe192-Val196, while the remaining eleven showed high b-factor values for this area, an additional hint for its flexibility. In the fully resolved structures the loop occurred as a disordered random coil. Moreover, the loop was found in a stable orientation only for ternary complexes, which had enzyme, cofactor and steroidal product or inhibitor fully resolved (1a27, 1fdtA, 1fdtB, 1equA, 1fduC and 3hb5; cluster cl2 in Figure 3). For all other crystal structures no univocal loop conformation could be ascribed to the presence of either cofactor or ligand. Nevertheless, this multiplicity of conformations suggested various substates for 17β-HSD1, which are subjected to fast dynamic motions and secondary structure rearrangements of the loop. Most of the binary complexes E-E2 were fully resolved, while the E-NAD(P)+ complexes lack part of the βFαG′-loop and no binary complex with NADPH or with E1 existed at all (Table 1). The existence of numerous fully resolved E-E2 complexes led us to speculate that NADPH became tightly bound to the enzyme only after the steroid had entered the cavity and the loop had changed its conformation. Interestingly, a similar behaviour was confirmed also by molecular dynamics of some complexes, as it will be elucidated later in this article.
Representative structures of the three βFαG′-loop conformations cl1 (yellow, 1iol), cl2 (magenta, 1a27) and cl3 (blue, 1i5r), clustered according to the backbone RMSD of the five residues Phe192-Val196. βFαG′-loop, αG′-helix (green) and C-terminal helix (cyan) are rendered as cartoon, NADPH and E1 as sticks and the rest of the enzyme (active site) as electrostatic surface.
The twelve full-length crystal structures of 17β-HSD1 were superimposed and clustered according to the backbone RMSD (mean value ca. 3 Å) of the five loop residues Phe192-Val196. Three clusters cl1, cl2 and cl3 (Figure 3; representative structures: 1iol, 1a27 and 1i5r, respectively) could be identified, as well as the presence of three gates, two close to the loop (gate 1 and 2) and a third one (gate 3) close to the C-terminal helix (Figure 4). However, this backbone classification disregarded active site volume changes and was limited to ascribe the presence of opened gates for the three clusters cl1–cl3. Thus, clustering was repeated taking into account all atoms of the same loop residues, which resulted in a mean RMSD value of ca. 6 Å. Five clusters could be identified (Figure 4 and S3) and Phe192, in particular, emerged as an important marker for the conformational variations, since its side chain presented the largest RMSD deviation (ca. 10 Å) rotating for about 200 degrees around the loop axis (Figure S4 and Video S1): it turned from the inner cavity, where it occluded the SUB and stabilized the substrate in the correct position for hydride transfer (1fdtB), toward the outside, where it chaperones E1/E2 or the cofactor in and out of the active site (1fdtA). These two extremes in the orientation of the side chain of Phe192 corresponded to the major changes of the active site volumes of all wild type E-NADPH-E2 complexes, where the volume ratio SUB/COF changed from 30∶70 in 1fdtB to 37∶63 in 1fdtA (Table 1).
To each step one or more crystal structures were assigned. Side chains of the βFαG′-loop residues Phe192-Lys195 are rendered as sticks and the orientation of the loop (blue ball) with respect to the αG′ helix (in gray) is shown as cartoon. The arrows 1–3 indicate the entrance and egress gates identified along the reaction pathway. 1fdtA is not included in the balloon of step 4 due to its different loop axis orientation with respect to 1iol.
2. Which mechanisms govern the kinetic cycle of 17β-HSD1?
17β-HSD1 is described to follow a random bi-bi kinetic mechanism (Figure 4, S1 and S3) , . Based on biochemical and structural data (i.e. the excess of NADPH over E1 and the different crystal structures for the apo-, holo- and ternary form) we hypothesized 17β-HSD1 to follow a five-step preferential pathway in vivo. Moreover, we assigned enzyme conformations to the specific steps and tried to rationalize the reaction pathway according to the presence of cofactor, E1 or E2, as well as to the conformational changes expected to occur in order to allow the kinetic cycle to evolve further (in brackets the PDB id of the crystal structures best describing the starting conformer for each specific step).
2.1. Step 1 (1bhs).
We postulate that NADPH will bind first and, in particular, into the COF, when the βFαG′-loop is placed in cluster cl2/1, with gate 1 wide and accessible. The entrance of the cofactor and its interactions with the apoform of the enzyme might induce a conformational rearrangement of the flexible loop toward the COF, with the loop moving from cl2 into cl3, thus closing gate 1 and opening gate 2. This loop-motion is intended to favour the entrance and binding of E1.
2.2. Step 2 (1i5r).
E1 enters and the loop slides back to its starting point in cluster cl2/1, gate 2 will be closed again and the next step reached.
2.3. Step 3 (1fdtB, 1a27).
After the βFαG′-loop has allowed the entrance of E1, it orients Phe192 and Met193 inward in order to stabilize the substrate in an optimal position for the pro-S hydride transfer. The first ternary complex (E-NADPH-E1) is formed and the catalytic reaction takes place.
2.4. Step 4 (1fdtA, 1iol).
Now the flexible loop is expected to drift into cluster cl1, protruding more into the SUB and opening gate 1. This gate rules the egress path for NADP+, hence when it is open the oxidized cofactor can leave the active site. The steroid, however, is still stabilized in the SUB, shielded by Phe192 and Met193.
3. Validation of the catalytic cycle by means of molecular dynamic simulations
MD simulations have been proven to be very useful tools in the analysis of dynamic motions of enzymes with flexible loops, which might play a prominent role in either the catalytic cycle and/or ligand binding. In particular, kinetic cycle and ligand-binding related motions of E. coli ,  have been intensively studied by means of both experimental and computational methods. While the former (such as site-directed mutagenesis, isothermal calorimetry, NMR dispersion, crystallography, etc.) constituted the basis for the understanding of DHFR functionality and catalytic mechanism, the computational methods (such as MD simulations, thermal fluctuation, free energy calculations, etc.) were applied with success in order to elucidate protein plasticity and allosteric mechanism. Moreover, they were envisaged to address new strategies in drug design, as for example the inhibition of E. coli DHFR by functional disruption, where the enzyme is frozen in a conformer that stops the kinetic cycle .
Herein, we applied MD simulations and free energy calculations pursuing as a main goal to substantiate the assignment of different enzyme conformations of 17β-HSD1 to the five steps encountered along its catalytic pathway. Moreover, we wanted to investigate transition steps and enzyme motions influenced by starting conformation and ligand binding. To this end, eight MD simulations (models I-III; Text S1) were designed based on the crystal structures 1fdtA, 1i5r, 1fdtB, and 1bhs, which differ strongly in the orientation of the βFαG′-loop (Figure 3, 4 and S3). In fact, the enzyme was investigated in its opened-state (1fdtA) - characterized by a fused COF and SUB and by Phe192 turned outward, in a semi-opened/occluded state (1i5r) - with the loop shifted toward the COF and Phe192 more buried than in 1fdtA, and in its closed-state (1fdtB) - mimicking the catalytic moment with a closed SUB and Phe192 pointing inward perpendicular to the catalytic Tyr155. The MD simulations of apoform E (A), binary E-NADPH (B) and ternary complexes E-NADPH-E1 (C) of 17β-HSD1 were evaluated in terms of geometry (RMSD) and energy stability of the complexes, ligand and secondary structure displacement with respect to the starting pose, and the time required to reach a stable RMSD and energy plateau. For each stable sector of the MD trajectories absolute free energy (ΔG) and relative binding affinity (ΔGbind) were calculated by means of MM-PBSA methods and NMODE analysis. Thus, in order to determine whether a preferential enzyme conformation exists for the binding of NADPH and E1, we compared ΔG and ΔGbind values of the binary complexes B1–B3 and of the ternary C1–C3, respectively (Table 2).
3.1 Step 1.
The MDs performed for step 1 pursued two main goals. First, we wanted to identify the enzyme conformation best representing the enzyme in its apoform and, thus, the folding that the flexible βFαG′-loop will adopt in absence of other ligands. And second, we expected to find an easily accessible COF, and eventually SUB, in the stable parts of the trajectories, as a consequence of opened gates 1 and 2.
Two MD simulations were performed with the enzyme only (1bhs – A1, 1fdtB – A2; Figure S5). In the apoform crystal structure 1bhs (A1) the fully resolved βFαG′-loop laid in cluster cl1, presenting a turn-helix-turn motif and the side chains of its residues oriented along its axis. Thus, a 12 ns MD A1 was performed in order to verify the reliability of 1bhs as step 1 enzyme conformation. Remarkably, the loop evolved toward cluster cl2, shielding the COF and especially the area where the nicotinamide moiety is found. This led to a large active site suitable to host both cofactor and ligand. The enzyme showed the tendency to preserve the hydrophobic character of the SUB, turning the side chains of the apolar residues (mostly Phe192, Phe226 and Phe259) inward, which occluded the SUB and avoided water to be placed in there. Met193 was also deeply buried in the SUB, occupying the space where steroids are normally placed. On the contrary, all polar residues belonging to the FG segment and to the C-terminal helix turned outside forming ion-pairs responsible for the closure of gate 2 and 3. The final stable complex of this MD was considered as a transition state of step 1, with an accessible COF, suitable to host NADPH, and an occluded SUB, not ready to accommodate the substrate. According to our hypothetic cycle, the βFαG′-loop should drift now further toward the COF (i.e. into cluster cl3), in concert and/or slightly delayed to NADPH entrance, resulting in a progressive closure of the COF (closed gate 1) and accessibility of the SUB (opening of gate2; 1i5r).
The second MD A2 was performed on the apoform of the closed-state conformation 1fdtB, stripped of both cofactor and steroid. The aim was to investigate whether the starting enzyme conformations of A1 and A2 would lead to different final tertiary structures or if they could converge to a common folding and loop axis orientation. However, already after 1 ns of simulation a marked change in the tertiary structure of the 1fdtB apoform was observed involving FG segment and C-terminal helix. Phe192 remained turned inward, while Met193 rotated out toward the αG′-helix, becoming responsible for the disruption of the αG′-helix.
The two simulations did not converge to a common conformation; moreover, the final complex of A2 resulted in a partially unfolded structure. This result suggested that the presence of cofactor and/or ligand would be necessary to assure a correct transition between the five steps of the enzymatic cycle and that the choice of the starting conformation might be crucial as well. The stable trajectory of A1, however, represents a nice simulation of step 1, especially if the exposed COF is considered.
3.2. Step 2.
In step 2 the COF should already be occluded and gate 1 being closed by the motion of the flexible loop into cl3. The loop should stabilize NADPH in the COF, and also maintain the substrate in the SUB in a correct position for the hydride transfer. The latter requires the loop to float again into cluster cl2, thus centrally placed.
Three 9 ns MDs were carried out on the binary complex E-NADPH (B) and another three, lasting 10 ns, on the ternary complex E-NADPH-E1 (C), with the enzyme in its opened (1fdtA - B1, C1), semi-opened (1i5r - B2, C2) and closed (1fdtB - B3, C3) state, respectively. The aim was to obtain insights into the role played by the loop in the stabilization of NADPH, the shielding of the SUB and the stabilization of E1.
Simulation B2 (1i5r-NADPH) was characterized by a quickly reached, very long stable RMSD plateau (Figure S6), indicating a good stability of the complex. Also the loop showed a stable RMSD profile, although, while the lower part (Glu194-Ser199) still remained close to the cofactor in cluster cl3, the upper part (Thr190-Met193) drifted toward the αG′-helix. This seemed to occur as a direct consequence of the outward rotation of Phe226, which was responsible to sustain the nicotinamide moiety in the starting complex, but which was also involved in opening gate 2, a prerequisite for E1 entrance. The loop was folded to a short helix and stabilized by the ion-pair Lys195 and 2′-phosphate of the cofactor, which trapped the adenosine moiety. In the final structure the upper part of the loop, placed in cluster cl2, occluded part of gate 2, reducing the solvent accessible surface and preserving the hydrophobic character of the SUB. Nevertheless, a hydrophobic tunnel remained open between loop and helix, suitable for steroid transition. The complex stability of B2 was also reflected by a good free energy ΔG (−9.35 kcal/mol) with respect to the positive values of B1 and B3 (Table 2), which substantiated our structural hypothesis for catalytic step 2.
The MD of the ternary complex 1i5r-NADPH-E1 (C2) described very well the expected loop motion from cluster cl3, shielding the COF, to cluster cl2 (Figure 5). Despite a suboptimal ΔG (−0.96 kcal/mol; but with a good ΔGbind of −23.68 kcal/mol) compared to that of the closed-state complex C3 (−8.31 kcal/mol), we considered the MD C2 as a valuable simulation of step 2 from a binary state to the ternary complex (Figure 5B). Effectively, this simulation ended with a stable complex in which E1 was properly bound into the SUB, involved into an h-bond network with Ser142/Tyr155 and His221/Glu282. Furthermore, the βFαG′-loop drifted into cl2 shielding the active site and forming a short α-helix, characteristic for most of the ternary complexes present in the PDB.
(A) The overlay of multiple snapshots of the trajectory C2 showed the transition of the loop axis from cluster cl3 to cl2 (color-coded in a range from red to blue, according to start and end of the MD, respectively). (B) Important active site residues of the initial (violet, step 1), stable (orange, step 2) and final complex (yellow) are rendered as sticks.
3.3. Step 3.
In this step the hydride transfer is meant to take place, thus no major tertiary structure rearrangements were expected.
The three MDs of the ternary complex E-NADPH-E1 (C1–C3; Figure S7) highlighted very well the important role of Phe192 and Met193 in stabilizing E1 close to the cofactor to ensure an optimal distance necessary for hydride transfer. When these two residues were turned outward, as it happened for the opened and the semi-opened complexes 1fdtA-NADPH-E1 (C1) and 1i5r-NADPH-E1 (C2) respectively, E1 had more space to move at the beginning of the simulations and resulted less stably bound.
The catalytic residues Ser142, Tyr155, and Lys159 showed small RMSD values for all three ternary complexes, even after 10 ns of dynamics (Figure S7D). This observation was in accordance to experimental site-directed mutagenesis studies , where the enzymatic activity was abolished because of the mutation of one or more of these residues. Moreover, the conformational stability of these residues suggested them to be essential for the postulated catalytic mechanism (Figure 2) , while other regions, for example the βFαG′-loop, to be the driving force that keeps the catalytic cycle running. The trajectories observed for the FG-segment residues Phe192 (in particular), Lys195 and Phe226 in the three simulations C1–C3 overlapped nicely with their orientations in the eighteen enzyme conformations (Figure S4) and fitted very well with the conclusion of Mazza et al. , who suggested a direct involvement of Lys195 and Phe192 in the catalytic cycle.
Phe192 was meant to play a very important role not only in steroid stabilization, but also in the catalytic reaction itself. In most ternary complexes with E1, Phe192 pointed perpendicular toward Tyr155. In this T-shaped conformation, Phe192 is likely to increase the acidity of the phenol group of the catalytic Tyr155 from a pKa of ca 9 to 6 , which presumably might facilitate the hydride transfer to the estrone. The final pose of Phe192 in C2 and C3 was consistent with this observation and enforced its role in protecting the nicotinamide moiety and activating the catalysis.
3.4. Postulated entrance mechanism of E1.
The starting structures of the opened and the closed complexes C1 and C3 (1fdtB-NADPH-E1), respectively, presented the loop axis (main chain) in similar starting conformation (cluster cl2), but with the side chains of the loop residues oriented opposite. After ca. 9 ns the MD C1 presented a long, stable RMSD plateau (Figure S7B). However, when this simulation was prolonged to ca. 16.5 ns, the all-atom RMSD rose to 3.5 Å, mostly related to βFαG′-loop motions (Figure 6). In fact, the extended part of C1 was characterized by slow concerted motions of the FG-segment and the C-terminal helix, i.e. increasing loop RMSD in Figure 6B, which led to the opening of gate 2 (the loop moves toward the COF into cl3) and gate 3. Remarkably, concomitant to these rearrangements the ΔG increased from −2.6 (after 9 ns) to −6.02 kcal/mol (after 16.5 ns). A progressive loss of the hydrogen bond between E1 and Ser142 was observed in concert with the outward rotation of Met193, Phe192, and Phe226. Thus, E1 drifted beneath the cofactor, turning its D-ring toward gate 2. A “backward analysis” of the whole simulation C1, ending with a conformation similar to the starting one of C3 (1fdtB), led us to postulate a “pull-and-push” mechanism for E1 entrance (Figure S8): E1 enters the binding site through gate 2, pulled by the inward rotation of Lys195 to which the steroid is bound with the C17 carbonyl. This bond will be released once E1 is placed into the SUB and Lys195 could rotate further toward the 2′-phosphate of the cofactor to stabilize it. Thus, Phe192 turns inward drifting below the nicotinamide ring of NADPH pushing hereafter E1 into the SUB and reaching so a similar conformation as the starting structure of C3 (1fdtB-NADPH-E1). Other residues delimiting gate 2 might also adapt to the steroid, as for example Phe226, which turns from the outside to the inner cavity stabilizing E1 (stable complex of MD C3; in blue in Figure 7).
(A) Time-dependent all-atom RMSD for all residues of the ternary complexes C1 (1fdtA) (light green) and C3 (1fdtB) (red) and (B) for the βFαG′-loop residues 187–199 of C1 (dark green) and C3 (orange).
3.5. Step 4.
In step 4 we expected the βFαG′-loop to drift further toward the αG′-helix into cluster cl1, protruding slightly into the SUB and opening gate 1, and, as a direct consequence, that NADP(H) leaves the COF via gate 1.
Two out of the six binary and ternary MD simulations were meaningful for describing this step: 1fdtB-NADPH-E1 (C3), which confirmed the loop motion with subsequent opening of gate 1 and the drift of E2 toward gate 3; and 1fdtA-NADPH (B1), which showed the egress path of the cofactor due to gate 1 enlargement.
Although at this stage the steroid should be E2, we considered for step 4 the simulations C1–C3, where E1 and NADPH were used instead of E2 and NADP+. We consider this approximation as acceptable, because no differences between the hydrogen bond patterns of E1 and E2 with 17β-HSD1 exist and because forcefield based methods, such as MD simulation, are not sensitive enough to handle the electrostatic differences between ligand and cofactor forms . Moreover, in this study we focused on the role of βFαG′-loop residues in substrate binding and on the determination of protein-ligand binding thermodynamics, and not on the simulation of the hydride transfer in the E1-E2 reduction. For the latter high-level quantum chemical calculations would be required, capable of dealing with bond-formation and –breaking as well as of treating electrons explicitly, in contrast to force field-based methods which handle atoms. In all complexes, E1 was placed in the same pose, analogous to that of E2 in the crystals. As already seen, all the MDs C1–C3 reached a stable RMSD plateau after already 4 ns (Figure S7), maintaining E1 placed in the SUB, but the ΔG values for their stable segments varied notably (Table 2). The MD of the ternary complex C3 best described step 4 with an ΔG of −8.31 kcal/mol for the first 10 ns (ΔGbind −28.3 kcal/mol): E1 maintained its hydrogen bonds to Ser142/Tyr155 for the first 10 ns, until being pushed toward gate 3 and out of the SUB in the following 7 ns due to the loop motion toward the αG′-helix (Figure 7) and the inward rotation of Phe192 and Phe226.
On the other hand, in simulation 1fdtA-NADPH (B1), characterized at its beginning by a wide access to the COF due to the outward rotated Phe192, we observed a concerted opening of gate 1 and closing of gate 2 due to the shift of the loop axis toward the αG′-helix. Thus, after a gradual increase in the first 5 ns, the all-atom RMSD reached a plateau and maintained it until the end of the simulation. Differently, the cofactor RMSD continued to rise (Figure S6D), in accordance to the movement of NADPH out of the COF, which was facilitated by the outward rotated Arg37, not burying the adenosine moiety in the COF anymore. Notably, the cofactor-stabilizing role of Arg37 had been previously demonstrated by site-directed mutagenesis studies . The αG′-helix rotated slightly rightward for about 30 degrees, adapting its residues to those of the loop. In this motion, His221 moved outward, breaking the salt bridge with Glu282 and enlarging gate 3. The free energy of complex B1 (+35.53 kcal/mol) clearly indicates that this enzyme conformation is disfavoured to stabilize NADPH, which ends up solvent exposed, suggesting complex B1 to be a good model to simulate the exit of the cofactor in step 4.
3.6. Step 5.
At this stage we expected E2 (in our case E1) to exit the SUB via gate 3 as well as a concerted rearrangement of the FG-segment residues to shield the empty SUB.
MD simulation C3 was prolonged up to ca 17.5 ns, with the purpose to evaluate the propensity of E1 to escape the active site. While the all-atom RMSD of the extended part of C3 (10–17.5 ns) decreased (Figure 6A), its loop RMSD increased slowly (Figure 6B). This sector of the dynamic was characterized by the closure of gate 2, the opening of gate 3 and the concerted breaking of the hydrogen-bond network between E1, His221 and Glu282. In fact, in C3 E1 drifted toward gate 3 and stuck out of the SUB. The progression of E1 to the end of the tunnel was favoured by the loop motions, the rotation of the apolar residues Phe192, Met193 and Phe226 into the SUB (Figure 7), and by the edging out of His221 and Glu282 and the consequent enlargement of gate 3. Interestingly, a decrease of ΔG from −8.31 (after ca. 10 ns) to −6.36 kcal/mol (after 17 ns) was observed.
Ideally, the final structure of step 5 should be similar to the starting one of step 1. This could not be reached with our 10 ns MDs. The reasons therefore could be the presence of E1 in the SUB, influencing the loop motions, but also because a much longer simulation time would be required to sample such marked conformational changes. However, the final structure of C3 reveals opened gates 1 and 3 and an occluded gate 2, with the βFαG′-loop close to the αG′-helix, as observed for 1bhs, the representative crystal for step 1.
Very recently, a binary and a ternary complex of 17β-HSD1 (PDB entry 3hb4 and 3hb5) with the potent E2-derived inhibitor E2B were published . In the ternary structure the βFαG′-loop was oriented in cluster cl2, in analogy to all other ternary complexes, confirming its importance in ligand stabilization, in particular of Phe192 and Met193.
The results of the analysis of the crystal structures and of the multi-trajectory MD approach coupled with free energy calculations were in agreement with the biochemical data published so far and substantiated the random bi-bi kinetic cycle of 17β-HSD1. Our multi-trajectory approach allowed an accurate assignment of different enzyme conformers to each postulated step of the catalytic cycle of 17β-HSD1. The analysis of the different trajectories revealed an essential role for backbone and side chain motions, in particular of the flexible βFαG′-loop, in cofactor and substrate binding, and the existence of distinguished conformer ensembles related to the single steps of the catalysis. Thus, it suggested 17β-HSD1 to follow a selected-fit mechanism : E1 or NADPH binds to a transition state of the enzyme and induces concerted conformational rearrangements of FG-segment and C-terminal part, which then guides the enzyme along its preferred catalytic pathway. Furthermore, the enzyme-ligand (both NADPH and E1) motions observed in our MD study suggested a preferential pathway for this kinetic cycle, with the cofactor NADPH entering first, followed by the substrate E1, which then induces concerted enzyme adaptation to both ligands. Depending on the presence of E1 and/or NADPH these enzyme forms evolved into a favourable low energy conformations representative for the specific steps, as for example observed for the ternary complex 1I5R-NADPH-E1 (C2) where the flexible loop moved toward the αG′-helix stabilizing both the substrate E1 and the cofactor NADPH.
The small RMSD variations observed for the catalytic residues Ser142, Tyr155 and Lys159 in all MDs suggested other regions of the enzyme to be responsible for the proceeding of the five-step catalytic cycle. Site-directed mutagenesis studies indicated for His221 and Glu282 a prominent role in substrate recognition, but not in catalysis , –. The motions of His221 observed in the simulations were in agreement with these results and allowed interesting conclusions regarding the role of His221 in substrate recognition and with respect to its chaperone function in guiding E1 out of the SUB (Figure 7).
Ghosh et al. described two conformations for the βFαG′-loop (“substrate-entry loop”), an opened when no steroids are present and closed one with the steroid in the SUB , . On the contrary, in our study we identified three main βFαG′-loop axis and five different loop side-chains orientations, characteristic for five steps of the bi-bi kinetic cycle. Our multi-trajectory/-complex approach allowed us to sample a broad conformational space and all these conformers, together with the calculated ΔG values, substantiated the three cluster variant, with the enzyme in an opened (cl1), occluded (cl3) and closed (cl2) state, depending on the presence of steroid, cofactor-steroid or cofactor.
In conclusion, this study laid the basis not only for a better understanding of the kinetic cycle of 17β-HSD1 and of the role of some amino acids, in particular of Phe192, Met193, Lys195 and Phe226, but also for possible new design strategies to inhibit 17β-HSD1. Thus, the enzyme conformations assigned to the various steps might represent a valid starting point for the development of inhibitors disrupting the enzyme dynamics and thus inactivating it by freezing it in one conformer and avoiding the cycle to evolve further. However, direct experimental results are still needed for a final demonstration, and, in particular, site directed mutagenesis studies, as well as further computational investigations, are envisaged in order to strengthen our conclusions.
Materials and Methods
1. Computational Details
Crystal structures of 17β-HSD1 were obtained from the Protein Databank (PDB, www.pdb.org)  and further prepared using the BIOPOLYMER module of SYBYL v8.0 (Sybyl, Tripos Inc., St. Louis, Missouri, USA). In detail, we used the following PDB structures: 1a27, 1bhs, 1dht, 1equ, 1fds, 1fdtx2, 1fdu, 1fdv, 1fdw, 1i5r, 1iol, 1jtv, 1qyv, 1qyw, 1qyx, 3dhe, 3dey, 3hb4 and 3hb5. 1fdt presents Arg37 and the loop residues Thr190 to Gly198 in two very different conformations, denoted in this article as 1fdtA (open state) and 1fdtB (closed state). Water molecules, sulfate ions and the hydride inhibitor HYC (1i5r) were removed from the PDB files and missing protein atoms were added. E2 was modified to estrone E1 and NADP+ was turned into NADPH. Hydrogen atoms and neutral end groups were added. All basic and acidic residues were considered protonated and deprotonated, respectively. Histidines oriented toward the outer part of the enzyme were considered as protonated after a prediction run made by MolProbity . For 1i5r the cofactor NADPH was merged into the enzyme after an accurate overlay with the hybrid inhibitor HYC and the X-rays 1a27 and 1fdt. Further, every crystal structure was minimized for 500 steps with the steepest descent minimizer as implemented in SYBYL with the backbone atoms kept at fixed positions in order to fix close contacts, followed by 2000 steps conjugate gradient minimization requested for an overall better starting structure.
Ligands were described with the general Amber force field GAFF . RESP charges for estrone were calculated, while the parameters of Ulf Ryde were taken for NADPH (charge -4) (http://www.teokem.lu.se/~ulf/).
The clustering of the crystal structures of Table 1 has been performed by means of the CONSENSUS utility of the homology module of MOE (www.chemcomp.com) and resulted in the two different backbone and side-chain classifications.
2. MD simulations
Molecular dynamics (MD) and free energy computations were carried out using Amber 9.0 suite of programs  and the AMBER99SB force field . The simulation system was set up using the xLeap program of the AMBER suite. The simulation systems were surrounded by a truncated octahedral box of TIP-3 water molecules of 10 Å radius. Counterions were added to neutralize the system. Prior to the free MD simulations, the simulation systems were energy minimized for 5000 steps of steepest descent followed by 10000 steps of conjugate gradient optimization. The equilibration process was carried out with the program PMEMD on the NVT ensemble using the following procedure: the simulation system was heated during 200 ps from 0 to 200 K at constant volume conditions. This temperature was held for additional 200 ps and afterwards raised to 300 K during 200 ps at constant volume. Protein heavy atoms, NADPH and E1 were constraint, and the force constant was gradually reduced from 100 kcal/mol/Å2 to 2 kcal/mol/Å2. The final coordinates of the temperature equilibration routine were relaxed without restraint for other 50 ps and then used for the MD production run, performed at NPT physical conditions and without restraints. The total simulation length differed for the various complexes ranging from 9 to 17.5 ns. taup = 2.0 and cut = 10.0. Temperature regulation was done at 1.0 atm of pressure (1 atm = 101.3 kPa) by using a Langevin thermostat with a coupling constant of tautp = 1.5 ps. The time step of the free MD simulations was 2 fs, with a cutoff of 13 Å for the nonbonded interaction, and SHAKE  was employed to keep all bonds involving hydrogen atoms rigid. Electrostatic interactions were computed using the Particle Mesh Ewald method . All simulations were carried out in periodic boundary conditions.
3. Free energy calculations using the MM/PBSA method
Conventional MM-PBSA ,  and normal-mode (NMODE)  calculations were performed using the AMBER 9 suite. The electronic and Van der Waals energies were calculated by the sander module. The polar solvation energy was calculated with the finite-difference PB equation solver by using AMBER toolset.
For each stable sector of the MD trajectories B1–B3 and C1–C3, longer than 4 ns, snapshots were collected every 30th frame (every 30 ps) and used to calculate relative binding affinity (ΔGbind) and absolute free energy (ΔG) by means of MM-PBSA methods and NMODE. The normal mode analysis was performed to estimate the vibrational component of the entropy. Conjugate gradient and then Newton-Raphson minimizations until the root mean square of the elements of gradient vector was less than 5*10−5 kcal/mol were carried out in absence of solvent. A distance-dependent dielectric constant was used to mimic solvent screening. Frequencies of the vibrational modes were computed at 300 K for these minimized structures and using a harmonic approximation of the energies. Due to the high computational demand, only snapshots taken every 100th frame from MD were used to estimate -TΔS.
A more detailed description of MM/PBSA and NMODE is given in Text S2.
4. RESP charges
The ab-initio geometry optimizations for E1 was performed in gas phase at the B3LYP/6-311+g (d,p) level of density functional theory (DFT) by means of the Gaussian03 .
A detailed description of the multi-trajectory/-complex MD approach, classified as three models.
(0.10 MB DOC)
Additional informations to the methods (MM-PBSA and NMODE) used.
(0.09 MB DOC)
Random sequential bi-bi kinetic cycle of 17β-HSD1. The preferred pathway is represented in red, guided by the excess of NADPH compared to E1, and identified by the MD simulations A1–A2, B1–B3, and C1–C3. In vitro, where the concentrations of the reagents can be modified, different orders might also be possible.
(0.33 MB TIF)
Tertiary structure of 17β-HSD1. Rossmann fold, βFαG′-loop, αG′-helix are highlighted. E2 and NADP+ are rendered as sticks, whereas the enzyme as cartoons. Helices are colored red, β-sheets in yellow and coils in green). The active site surface is rendered as grey wireframes. (PDB entry 1a27.)
(0.74 MB TIF)
Schematic representation of the catalytic cycle of 17β-HSD1. (A) 2D-scheme of the structure of 17β-HSD1; including: Rossmann fold, cofactor binding site (COF; blue), substrate active site (SUB; green), alternative (fused COF-SUB) active site, αG′-helix (green ball), βFαG′-loop (yellow-red ball); gates 1 (blue), 2 (cyan) and 3 (magenta) are represented by arrows and e circles of the same color. (B–F) Representative conformations of the 5 steps of the catalytic cycle clustered accordingly to the side-chain RMSD. Detailed informations about the role of the βFαG′-loop in the various steps of the cycle are mentioned in the single charts. The circles represent gates 1–3, and they change in size depending whether they are opened or closed. The loop residues Phe192 (F), Met193 (M), Glu194 (E) and Lys195 (K) are schematized according to their effective distance from the loop axis at every step.
(4.90 MB TIF)
Morphing the transition from 1fdtA to 1fdtB. Different orientations of Phe192 for the 5 clusters obtained by all-atom RMSD classification of the five loop residues (rendered in sticks, color-coded blue-violet) and for the 17 intermediate positions (rendered in lines, magenta) obtained by simulating the transition from 1fdtA to 1fdtB, the two extremes in the Phe192 rotation, using the Yale Morph Server (Krebs WG, Gerstein M (2000). The morph server: a standardized system for analyzing and visualizing macromolecular motions in a database framework. Nucl Acids Res 28:1665–1675). A movie of this rotation is also available (Video S1).
(2.07 MB TIF)
Analysis of the MDs of the apoform complexes A1–A2. Time-dependent all-atom RMSD for (A) all residues of the complexes A1 (blue - 1bhs) and A2 (red - 1fdtB), and (B) only for the βFαG′-loop residues only. (C) Residue-dependent RMSD fluctuation for the three complexes A1–A2.
(3.69 MB TIF)
Analysis of the MDs of the binary complexes B1–B3. Time-dependent all-atom RMSD for the complexes (A) B2 (light blue all residues, dark blue βFαG′-loop), (B) B1 (light green all residues, dark green βFαG′-loop) and (C) B3 (red all residues, orange βFαG′-loop). (D) Time-dependent RMSD for NADPH of the three complexes B2 (blue), B1 (green) and B3 (red). (E) Residue-dependent RMSD fluctuation for the three complexes B1–B3 (same colors as for (D)).
(5.22 MB TIF)
Analysis of the MDs of the ternary complexes C1–C3. (A) Time-dependent all-atom RMSD for the complexes C2 (light blue all residues, dark blue βFαG′-loop), (B) C1 (light green all residues, dark green βFαG′-loop) and (C) C2 (red all residues, orange βFαG′-loop). (D) Residue-dependent RMSD fluctuation for the three complexes C1–C3.
(4.89 MB TIF)
Postulated entrance mechanism for E1. (A) Four snapshots of the MD C1 (1fdtA-NADPH-E1), with representative structures after (Ai) 12 ns (white), (Aii) 9 ns (yellow), (Aiii) 6 ns (magenta) and (Aiv) 3 ns (magenta). Surfaces of the ligand binding sites are shown in light grey. (B) Starting structure (violet) and stable complex after 10 ns (cyan) of MD C3 (1fdtB-NADPH-E1). Complexes are rendered in cartoon. NADPH, E1 and residues crucial for the dynamic are shown as sticks and labeled.
(3.91 MB TIF)
Morphing the transition from 1fdtA to 1fdtB.
(2.61 MB MPG)
We thank Dr. Sandrine Oberwinkler-Marchais for helpful discussion. MN is grateful for his co-tutelle PhD between the University of Bologna and Saarland University of which this work was a substantial part.
Conceived and designed the experiments: MN. Performed the experiments: MN. Analyzed the data: MN. Wrote the paper: MN MR RWH. Supervised MN: MR. Supervised MN.
- 1. Lerner MG, Bowman AL, Carlson HA (2007) Incorporating dynamics in E. coli dihydropholate reductase enhances structure-based drug discovery. J Chem Inf Model 47: 2358–2365.MG LernerAL BowmanHA Carlson2007Incorporating dynamics in E. coli dihydropholate reductase enhances structure-based drug discovery.J Chem Inf Model4723582365
- 2. Persson B, Kallberg Y, Bray JE, Bruford E, Dellaporta SL, et al. (2009) The SDR(short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. Chem Biol Interact 178: 94–98.B. PerssonY. KallbergJE BrayE. BrufordSL Dellaporta2009The SDR(short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative.Chem Biol Interact1789498
- 3. Mauldin RV, Carroll MJ, Lee AL (2009) Dynamic dysfunction in dihydrofolate reductase results from antifolate drug binding: modulation of dynamics within a structural state. Structure 17: 386–394.RV MauldinMJ CarrollAL Lee2009Dynamic dysfunction in dihydrofolate reductase results from antifolate drug binding: modulation of dynamics within a structural state.Structure17386394
- 4. Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, et al. (1997) The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 62: 148–158.F. LabrieV. Luu-TheSX LinC. LabrieJ. Simard1997The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology.Steroids62148158
- 5. Miettinen MM, Mustonen MV, Poutanen MH, Isomaa VV, Vihko RK (1996) Human 17 beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem J 314: 839–845.MM MiettinenMV MustonenMH PoutanenVV IsomaaRK Vihko1996Human 17 beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression.Biochem J314839845
- 6. Prehn C, Möller G, Adamski J (2009) Recent advances in 17beta-hydroxysteroid dehydrogenases. J Steroid Biochem Mol Biol 114(1–2): 72–77.C. PrehnG. MöllerJ. Adamski2009Recent advances in 17beta-hydroxysteroid dehydrogenases.J Steroid Biochem Mol Biol114(1–2)7277
- 7. Sasano H, Frost AR, Saitoh R, Harada N, Poutanen M, et al. (1996) Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endocrinol Metab 11: 4042–4046.H. SasanoAR FrostR. SaitohN. HaradaM. Poutanen1996Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma.J Clin Endocrinol Metab1140424046
- 8. Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y, et al. (2001) Involvement of up-regulation of 17 beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int J Cancer 94: 685–689.Y. MiyoshiA. AndoE. ShibaT. TaguchiY. Tamaki2001Involvement of up-regulation of 17 beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers.Int J Cancer94685689
- 9. Frotscher M, Ziegler E, Marchais-Oberwinkler S, Kruchten P, Neugebauer A, et al. (2008) Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases. J Med Chem 51: 2158–2169.M. FrotscherE. ZieglerS. Marchais-OberwinklerP. KruchtenA. Neugebauer2008Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases.J Med Chem5121582169
- 10. Marchais-Oberwinkler S, Kruchten P, Frotscher M, Ziegler E, Neugebauer A, et al. (2008) Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1): design, synthesis, biological evaluation, and pharmacokinetics. J Med Chem 51: 4685–4698.S. Marchais-OberwinklerP. KruchtenM. FrotscherE. ZieglerA. Neugebauer2008Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.J Med Chem5146854698
- 11. Day JM, Tutill HJ, Purohit A, Reed MJ (2008) Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer 15: 665–692.JM DayHJ TutillA. PurohitMJ Reed2008Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.Endocr Relat Cancer15665692
- 12. Kruchten P, Werth R, Bey E, Oster A, Marchais-Oberwinkler S, et al. (2009) Selective inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells. J Steroid Biochem Mol Biol 114: 200–206.P. KruchtenR. WerthE. BeyA. OsterS. Marchais-Oberwinkler2009Selective inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells.J Steroid Biochem Mol Biol114200206
- 13. Cooper WC, Jin Y, Penning TM (2007) Elucidation of a complete kinetic mechanism for a mammalian hydroxysteroid dehydrogenase (HSD) and identification of all enzyme forms on the reaction coordinate: the example of rat liver 3α-HSD (AKR1C9). J Biol Chem 282: 33848–33493.WC CooperY. JinTM Penning2007Elucidation of a complete kinetic mechanism for a mammalian hydroxysteroid dehydrogenase (HSD) and identification of all enzyme forms on the reaction coordinate: the example of rat liver 3α-HSD (AKR1C9).J Biol Chem2823384833493
- 14. Betz G (1971) Reaction mechanism of 17 beta-estradiol dehydrogenase determined by equilibrium rate exchange. J Biol Chem 246: 2063–2068.G. Betz1971Reaction mechanism of 17 beta-estradiol dehydrogenase determined by equilibrium rate exchange.J Biol Chem24620632068
- 15. Sherbet DP, Papari-Zareei M, Khan N, Sharma KK, Brandmaier A, et al. (2007) Cofactors, redox state, and directional preferences of hydroxysteroid dehydrogenases. Mol Cell Endocrinol 265–266: 83–88.DP SherbetM. Papari-ZareeiN. KhanKK SharmaA. Brandmaier2007Cofactors, redox state, and directional preferences of hydroxysteroid dehydrogenases.Mol Cell Endocrinol265–2668388
- 16. Penning TM (1997) Molecular endocrinology of hydroxysteroid dehydrogenases. Endcrin Rev 18: 281–305.TM Penning1997Molecular endocrinology of hydroxysteroid dehydrogenases.Endcrin Rev18281305
- 17. Agarwal AK, Auchus RJ (2005) Minireview: Cellular redox state regulates hydroxysteroid dehydrogenase activity and intracellular hormone potency. Endocrinology 146: 2531–2538.AK AgarwalRJ Auchus2005Minireview: Cellular redox state regulates hydroxysteroid dehydrogenase activity and intracellular hormone potency.Endocrinology14625312538
- 18. Sherbet DP, Guryev OL, Papari-Zareei M, Mizrachi D, Rambally S, et al. (2009) Biochemical factors governing the steady-state estrone/estradiol ratios catalyzed by human 17β-hydroxysteroid dehydrogenases types 1 and 2 in HEK-293 cells. Endocrinology 150: 4154–4162.DP SherbetOL GuryevM. Papari-ZareeiD. MizrachiS. Rambally2009Biochemical factors governing the steady-state estrone/estradiol ratios catalyzed by human 17β-hydroxysteroid dehydrogenases types 1 and 2 in HEK-293 cells.Endocrinology15041544162
- 19. Ghosh D, Pletnev VZ, Zhu DW, Wawrzak Z, Duax WL, et al. (1995) Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 Å resolution. Structure 3: 503–513.D. GhoshVZ PletnevDW ZhuZ. WawrzakWL Duax1995Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 Å resolution.Structure3503513
- 20. Gangloff A, Garneau A, Huang Y-W, Yang F, Lin S-X (2001) Human oestrogenic 17β-hydroxysteroid dehydrogenase specificity: enzyme regulation through an NADPH-dependent substrate inhibition towards the highly specific oestrone reduction. Biochem J 356: 269–276.A. GangloffA. GarneauY-W HuangF. YangS-X Lin2001Human oestrogenic 17β-hydroxysteroid dehydrogenase specificity: enzyme regulation through an NADPH-dependent substrate inhibition towards the highly specific oestrone reduction.Biochem J356269276
- 21. Jin JZ, Lin S-X (1999) Human estrogenic 17β-hydroxysteroid dehydrogenase: predominance of estrone reduction and its induction by NADPH. Biochem Biophys Res Commun 259: 489–493.JZ JinS-X Lin1999Human estrogenic 17β-hydroxysteroid dehydrogenase: predominance of estrone reduction and its induction by NADPH.Biochem Biophys Res Commun259489493
- 22. Puranen T, Poutanen M, Ghosh D, Vihko P, Vihko R (1997) Characterization of structural and functional properties of human 17β-hydroxysteroid dehydrogenase type 1 using recombinant enzymes and site-directed mutagenesis. Mol Endocrinol 11: 77–86.T. PuranenM. PoutanenD. GhoshP. VihkoR. Vihko1997Characterization of structural and functional properties of human 17β-hydroxysteroid dehydrogenase type 1 using recombinant enzymes and site-directed mutagenesis.Mol Endocrinol117786
- 23. Brozic P, Lanisnik Rizner T, Gobec S (2008) Inhibitors of 17β-hydroxysteroid dehydrogenase type 1. Curr Med Chem 15: 137–150.P. BrozicT. Lanisnik RiznerS. Gobec2008Inhibitors of 17β-hydroxysteroid dehydrogenase type 1.Curr Med Chem15137150
- 24. Bey E, Marchais-Oberwinkler S, Werth R, Negri M, Al-Soud YA, et al. (2008) Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). J Med Chem 51: 6725–6739.E. BeyS. Marchais-OberwinklerR. WerthM. NegriYA Al-Soud2008Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).J Med Chem5167256739
- 25. Bey E, Marchais-Oberwinkler S, Negri M, Kruchten P, Oster A, et al. (2009) New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitory activity and selectivity. J Med Chem 52: 6724–6743.E. BeyS. Marchais-OberwinklerM. NegriP. KruchtenA. Oster2009New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitory activity and selectivity.J Med Chem5267246743
- 26. Poirier D (2009) Advances in development of inhibitors of 17β-hydroxysteroid dehydrogenases. Anticancer Agents Med Chem 9: 642–660.D. Poirier2009Advances in development of inhibitors of 17β-hydroxysteroid dehydrogenases.Anticancer Agents Med Chem9642660
- 27. Poirier D, Boivin RP, Tremblay MR, Bérubé M, Qiu W, et al. (2005) Estradiol-adenosine hybrid compounds designed to inhibit type 1 17β-hydroxysteroid dehydrogenase. J Med Chem 48: 8134–8147.D. PoirierRP BoivinMR TremblayM. BérubéW. Qiu2005Estradiol-adenosine hybrid compounds designed to inhibit type 1 17β-hydroxysteroid dehydrogenase.J Med Chem4881348147
- 28. Karkola S, Lilienkampf A, Wähälä K (2008) A 3D QSAR model of 17β-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking. Chem Med Chem 3: 461–472.S. KarkolaA. LilienkampfK. Wähälä2008A 3D QSAR model of 17β-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking.Chem Med Chem3461472
- 29. Messinger J, Hirvelä L, Husen B, Kangas L, Koskimies P, et al. (2006) New inhibitors of 17β-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 248: 192–198.J. MessingerL. HirveläB. HusenL. KangasP. Koskimies2006New inhibitors of 17β-hydroxysteroid dehydrogenase type 1.Mol Cell Endocrinol248192198
- 30. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, et al. (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33: 889–897.PA KollmanI. MassovaC. ReyesB. KuhnS. Huo2000Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models.Acc Chem Res33889897
- 31. Case DA (1999) Rigidity Theory and Applications. Thorpe MF, Duxbury PM, editors. pp. 329–344.DA Case1999MF ThorpePM DuxburyRigidity Theory and Applications329344(Plenum, New York). (Plenum, New York).
- 32. Jornvall H, Persson B, Krook M, Atrian S, Gonzalez-Duarte R, et al. (1995) Short-chain dehydrogenases/reductases (SDR). Biochemistry 34: 6003–6013.H. JornvallB. PerssonM. KrookS. AtrianR. Gonzalez-Duarte1995Short-chain dehydrogenases/reductases (SDR).Biochemistry3460036013
- 33. Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, et al. (2006) CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucl Acids Res 34: W116–W118.J. DundasZ. OuyangJ. TsengA. BinkowskiY. Turpaz2006CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues.Nucl Acids Res34W116W118
- 34. Mazza C (1997) Human type 1 17 beta-hydroxysteroid dehydrogenase: site directed mutagenesis and x-ray crystallography structure-function analysis. C. Mazza1997Human type 1 17 beta-hydroxysteroid dehydrogenase: site directed mutagenesis and x-ray crystallography structure-function analysis.DOI:10.2210/pdb1a27/pdb. DOI:10.2210/pdb1a27/pdb.
- 35. Han Q, Campbell RL, Gangloff A, Huang YW, Lin SX (2000) Dehydroepiandrosterone and dihydrotestosterone recognition by human estrogenic 17beta-hydroxysteroid dehydrogenase. C-18/C19 steroid discrimination and enzyme-induced strain. J Biol Chem 275: 1105–1111.Q. HanRL CampbellA. GangloffYW HuangSX Lin2000Dehydroepiandrosterone and dihydrotestosterone recognition by human estrogenic 17beta-hydroxysteroid dehydrogenase. C-18/C19 steroid discrimination and enzyme-induced strain.J Biol Chem27511051111
- 36. Sawicki MW, Erman M, Puranen T, Vihko P, Ghosh D (1999) Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+. Proc Natl Acad Sci USA 96: 840–845.MW SawickiM. ErmanT. PuranenP. VihkoD. Ghosh1999Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+.Proc Natl Acad Sci USA96840845
- 37. Breton R, Housset D, Mazza C, Fontecilla-Camps JC (1996) The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors. Structure 4: 905–915.R. BretonD. HoussetC. MazzaJC Fontecilla-Camps1996The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors.Structure4905915
- 38. Mazza C, Breton R, Housset D, Fontecilla-Camps JC (1998) Unusual Charge Stabilization of NADP+ in 17β-Hydroxysteroid Dehydrogenase. J Biol Chem 273: 8145–8152.C. MazzaR. BretonD. HoussetJC Fontecilla-Camps1998Unusual Charge Stabilization of NADP+ in 17β-Hydroxysteroid Dehydrogenase.J Biol Chem27381458152
- 39. Qiu W, Campbell RL, Gangloff A, Dupuis P, Boivin RP, et al. (2002) A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity. Faseb J 16: 1829–1831.W. QiuRL CampbellA. GangloffP. DupuisRP Boivin2002A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity.Faseb J1618291831
- 40. Azzi A, Rehse PH, Zhu DW, Campbell RL, Labrie F, et al. (1996) Crystal structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase complexed with 17 beta-estradiol. Nat Struct Biol 3: 665–668.A. AzziPH RehseDW ZhuRL CampbellF. Labrie1996Crystal structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase complexed with 17 beta-estradiol.Nat Struct Biol3665668
- 41. Gangloff A, Shi R, Nahoum V, Lin S-X (2003) Pseudo-symmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17beta-hydroxysteroid dehydrogenase. Faseb J 17: 274–276.A. GangloffR. ShiV. NahoumS-X Lin2003Pseudo-symmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17beta-hydroxysteroid dehydrogenase.Faseb J17274276
- 42. Shi R, Lin S-X (2004) Cofactor hydrogen bonding onto the protein main chain is conserved in the short chain dehydrogenase/reductase family and contributes to nicotinamide orientation. J Biol Chem 279: 16778–16785.R. ShiS-X Lin2004Cofactor hydrogen bonding onto the protein main chain is conserved in the short chain dehydrogenase/reductase family and contributes to nicotinamide orientation.J Biol Chem2791677816785
- 43. Mazumdar M, Aka J, Poirier D, Lin S-X (2009) 17β-HSD1 stimulates breast cancer by DHT inactivation in addition to estradiol production. M. MazumdarJ. AkaD. PoirierS-X Lin200917β-HSD1 stimulates breast cancer by DHT inactivation in addition to estradiol production.DOI:10.2210/pdb3dey/pdb. DOI:10.2210/pdb3dey/pdb.
- 44. Mazumdar M, Fournier D, Zhu D-W, Cadot C, Poirier D, et al. (2009) Binary and ternary crystal structure analyses of a novel inhibitor with 17β-HSD type 1: a lead compound for breast cancer therapy. Biochem J 424: 357–366.M. MazumdarD. FournierD-W ZhuC. CadotD. Poirier2009Binary and ternary crystal structure analyses of a novel inhibitor with 17β-HSD type 1: a lead compound for breast cancer therapy.Biochem J424357366
- 45. Aka JA, Mazumdar M, Chen CQ, Poirier D, Lin S-X (2010) 17β-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production. Mol Endocrinol 24: 832–845.JA AkaM. MazumdarCQ ChenD. PoirierS-X Lin201017β-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production.Mol Endocrinol24832845
- 46. Bennett MJ, Schlegel BP, Jez JM, Penning TM, Lewis M (1996) Structure of 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase complexed with NADP+. Biochemistry 35: 10702–10711.MJ BennettBP SchlegelJM JezTM PenningM. Lewis1996Structure of 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase complexed with NADP+.Biochemistry351070210711
- 47. Ibarra CA, Chowdhury P, Petrich JW, Atkins WM (2003) The anomalous pKa of Tyr9 in Glutathione S-Transferase A1-1 Catalyzes Product Release. J Biol Chem 278: 19257–19265.CA IbarraP. ChowdhuryJW PetrichWM Atkins2003The anomalous pKa of Tyr9 in Glutathione S-Transferase A1-1 Catalyzes Product Release.J Biol Chem2781925719265
- 48. Weikl TR, von Deuster C (2009) Selected-fit versus induced-fit protein binding: kinetic differences and mutational analysis. Proteins 75: 104–110.TR WeiklC. von Deuster2009Selected-fit versus induced-fit protein binding: kinetic differences and mutational analysis.Proteins75104110
- 49. Ghosh D, Vikho P (2001) Molecular mechanism of estrogen recognition and 17-keto reduction by human 17β-hydroxysteroid dehydrogenase 1. Chem Biol Interact 130–132: 637–650.D. GhoshP. Vikho2001Molecular mechanism of estrogen recognition and 17-keto reduction by human 17β-hydroxysteroid dehydrogenase 1.Chem Biol Interact130–132637650
- 50. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucl Acids Res 28: 235–242.HM BermanJ. WestbrookZ. FengG. GillilandTN Bhat2000The Protein Data Bank.Nucl Acids Res28235242
- 51. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, et al. (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucl Acids Res 35: W375–W383.IW DavisA. Leaver-FayVB ChenJN BlockGJ Kapral2007MolProbity: all-atom contacts and structure validation for proteins and nucleic acids.Nucl Acids Res35W375W383
- 52. Wang JM, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25: 1157–1174.JM WangRM WolfJW CaldwellPA KollmanDA Case2004Development and testing of a general amber force field.J Comput Chem2511571174
- 53. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, et al. (2006) DA CaseTA DardenTE CheathamCL SimmerlingJ. Wang2006Amber 9, University of California, San Francisco. Amber 9, University of California, San Francisco.
- 54. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65: 712–725.V. HornakR. AbelA. OkurB. StrockbineA. Roitberg2006Comparison of multiple Amber force fields and development of improved protein backbone parameters.Proteins65712725
- 55. Ryckaert JP, Ciccotti G, Berendsen JC (1977) J Comput Phys 23: 327–341.JP RyckaertG. CiccottiJC Berendsen1977J Comput Phys23327341
- 56. Darden T, Perera L, Li L, Pedersen L (1999) New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. Structure 7: R55–R60.T. DardenL. PereraL. LiL. Pedersen1999New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations.Structure7R55R60
- 57. Feig M, Karanicolas J, Brooks CL 3rd (2004) MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology. J Mol Graph Model 22: 377–395.M. FeigJ. KaranicolasCL Brooks 3rd2004MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology.J Mol Graph Model22377395
- 58. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33–38.W. HumphreyA. DalkeK. Schulten1996VMD: visual molecular dynamics.J Mol Graph143338
- 59. Srinivasan J, Cheatham TE III, Cieplak P, Kollman PA, Case DA (1998) Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices. J Am Chem Soc 120: 9401–9409.J. SrinivasanTE Cheatham IIIP. CieplakPA KollmanDA Case1998Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices.J Am Chem Soc12094019409
- 60. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, et al. (2003) MJ FrischGW TrucksHB SchlegelGE ScuseriaMA Robb2003Gaussian, Inc.: Pittsburgh, PA. Gaussian, Inc.: Pittsburgh, PA.